Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells
Frontiers in Pharmacology · 16.07.2026 · 17
DOI: 10.3389/fphar.2026.1818890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.07.2026. Verfasst von Yi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer (BC) is the most commonly diagnosed cancer and the leading cause of cancer deaths among women worldwide. This study investigates the combined effects of tannic acid (TA) and doxorubicin (DOX) on glucose metabolism in estrogen receptor-positive (MCF7) and triple-negative (MDA-MB-231) BC cells by targeting pyruvate kinase M2 (PKM2). Cells were treated with TA, DOX, and their combinations, then analyzed for cytotoxicity, apoptosis, cell cycle progression, migration, and colony formation. PKM2 expression levels and activity were also measured. Results demonstrated that TA, alone and with DOX, effectively induced apoptosis and inhibited migration and colony formation in both cell lines. Notably, PKM2 mRNA expression was significantly reduced, particularly in TA-treated groups. Furthermore, glucose levels in the medium increased significantly following TA treatment, indicating reduced glucose uptake by cancer cells, and indicating that combining TA with DOX can disrupt glucose metabolism and diminish aggressive behaviors in BC cells. By targeting the glycolytic enzyme PKM2, TA lowers its expression, restricts glucose uptake, and enhances chemotherapy-driven apoptosis while limiting migration and colony formation. These findings underscore the potential of metabolic reprogramming through combining TA with DOX as a promising therapeutic strategy to improve BC treatment outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
- Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, China.
- Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.
- Molecular Biology Unit, Medical Technology Centre, Medical Research Institute, Alexandria University, Alexandria, Egypt.
- Research Institute for Electronic Science, Hokkaido University, Sapporo, Japan.
- Department of Histology, Faculty of Veterinary Medicine, Zagazig University, Egypt.
Zitieren
APA
Wang, Y., El-Far, A., Warda, A. A., Mohamed, S. A., Maghsoudloo, M., Hashim, P. K., Elewa, Y. H. A., Elmetwalli, A., Al Jaouni, S. K., & Zhao, W. (2026). Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1818890
Vancouver
Wang Y, El-Far A, Warda AA, Mohamed SA, Maghsoudloo M, Hashim PK, et al. Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1818890
BibTeX
@article{Wang2026,
author = {Wang, Yi and El-Far, Ali and Warda, Ahmed A and Mohamed, Shymaa A and Maghsoudloo, Mazaher and Hashim, P K and Elewa, Yaser H A and Elmetwalli, Alaa and Al Jaouni, Soad K and Zhao, Wenhong},
title = {Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1818890}
}
EUVIMED